DUOTRAV EYE DROPS 2.5 ML

* DUOTRAV (travoprost/timolol) 40 micrograms/ml + 5 mg/ml eye drops, solution. 2.5 ml. Ocular use.
* 1 ml of solution contains: 40 micrograms of travoprost and 5 mg timolol (as timolol maleate).
* Contains: Benzalkonium chloride, mannitol, trometamol, polyoxyethylene hydrogenated castor oil 40 (HCO-40),
boric acid, disodium edetate, trometamol and/or hydrochloric acid (to adjust pH) and purified water.
* Therapeutic Indications: Decrease of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
*Psology and method of administration:
# Use in adults, including the elderly: The dose is one drop of DuoTrav in the conjunctival sac of the affected eye(s) once daily,
in the morning or evening. It should be administered at the same time each day.
– Nasolacrimal occlusion or gently closing the eyelid after administration is recommended. This may reduce the systemic
absorption of medicinal products administered via the ocular route and result in a decrease in systemic adverse effects.
– If more than one topical ophthamic medicinal product is being used, the medicinal products must be administered at least
5 minutes apart.
– If a dose is missed, tearment should be continued with the next dose as planned. The dose should not exceed one drop
in the affected eye(s) daily.
When substituting another ophthalmic antiglaucoma agent with DuoTrav, the other agent should be discontinued and
DurTrav should be started the following day.
# Pediatric patients: the efficacy and safety of DuoTrav in patients below the age of 18 years have not been established
and its use is not recommended in these patients until further data become availabe.
# Use in hepatic and renal impairment: No studies have been conducted with DuoTrav or with Timolol 5mg/mL eye drops
in patients with hepatic or renal impairment. Travoprost has been studied in patients with mild to severe hepatic impairment
and in patients with mild to renal impairment (creatinine clearance as low as 15mL/min). No medication adjustment
was necessary in these patients.
* Contraindications:
Hypersensitivity to travoprost, timolol or any of the excipients.
– Bronchial asthma, a history of bronchial asthma or severe chronic obstructive pulmonary disease.
Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock.
Severe allergic rhinitis and bronchial hyper reactivity, corneal dystrophies, hypersensitivity to other beta-blockers.
* Medicinal product subject to medical prescription.
* Discard 4 weeks after first opening.
* Storage: Store at 2 – 25 degrees C.